الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 258 |  |  |
| | | from | 258 | | |
Abstract
Etodolac (ETD) is a non steroidal anti-inflammatory drug used for the acute and chronic treatment of rheumatoid arthritis (RA). It exhibits poor water solubility so its bioavailability is limited. Long term use of ETD causes serious gastrointestinal disturbance, which makes it a good candidate for transdermal formulations. Lecithin organogels (Los) have generated considerable interest over the years as potential topical drug delivery vehicle. Therefore, the aim of this study was to formulate ETD in lecithin organogels as a transdermal delivery system. Pseudoternary phase diagram was constructed using isopropyl myristate (IPM), water and lecithin as a surfactant with different cosurfactants (CoS) namely ethanol, propylene glycol (PG) and polyethylene glycol (PEG 400). Organogel areas were identified and three systems each of 36 formulae were prepared. The optimum organogel formulae were assessed for visual inspection, spreadability, pH measurement, droplet size analysis, rheological and in vitro drug release studies. According to the previous studies, the optimum three formulae were chosen (F3, F14 & F39) for ex-vivo permeation through excised abdominal rabbit skin. On the other hand, there stability were attained after one year of storage under ambient condition. The therapeutic efficacy of ETD in the selected formulae was monitored and compared with that of the market capsule by measuring its analgesic activity and anti-inflammatory effect in test animals. Statistical analysis of the data revealed the significant difference (p˂ 0.05) of therapeutic efficacy of F14 compared with other selected formula or market formula. Skin irritation test and histopathological studies revealed safety of F14. These results indicated the possibility of utilizing a formula containing (10% IPM, 40% lecithin/ethanol in the ratio of (5:1) and 50% water) that could successfully achieve sustained release as transdermal delivery system for ETD with good stability, non irritant, good bioavailability which is considered satisfactory for patient use.